{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-074706","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2024-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.986124+00:00","generated_at":"2026-06-04T09:04:40.453911+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Intellia terminates Factor IX co-development agreement with Regeneron; retains milestone/royalty rights under LCA","bullets":["On March 19, 2024, Intellia gave notice to Regeneron to exit the Factor IX Co-Development and Co-Funding Agreement, effective after 180 days.","Intellia will no longer share 35% of development costs or receive 35% of profits for Factor IX gene editing products upon termination.","Under the existing License and Collaboration Agreement (LCA), Intellia remains eligible for up to $320M in milestones and high-single to low-teen royalties.","Other collaboration programs with Regeneron under the LCA are unaffected by this termination."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-074706","json":"https://secwatch.observer/filing/0001193125-24-074706.json","markdown":"https://secwatch.observer/filing/0001193125-24-074706.md","text":"https://secwatch.observer/filing/0001193125-24-074706.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000119312524074706/0001193125-24-074706-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000119312524074706/d17601d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:04:40.453911+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8ba5bb85dc86ea9fe48dd4e4f8d706a9ba87db2a","claim":"Intellia Therapeutics, Inc. terminated Factor IX Co-Development and Co-Funding Agreement with Regeneron Pharmaceuticals, Inc. (effective 2024-03-19).","evidence_excerpt":"On March 19, 2024, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) notified Regeneron Pharmaceuticals, Inc. (“Regeneron”) that the Company is opting out of its Factor IX Co-Development and Co-Funding Agreement (the “Co-Co Agreement”), which the Company and Regeneron entered into in May 2020.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312524074706/0001193125-24-074706-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Regeneron Pharmaceuticals, Inc."},{"label":"Effective","value":"2024-03-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}